Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-207666
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Net cash used in operating activities | (40,878) | (22,020) |
| Cash flows from investing activities | ||
| Purchase of research and development license | (3,000) | — |
| Purchase of property, plant and equipment | (24) | (378) |
| Other | — | 7 |
| Net cash used in investing activities | (3,024) | (371) |
| Cash flows from financing activities | ||
| Payment of shelf registration costs | — | (47) |
Item 1. Financial Statements.
FAQ
- What is Taysha Gene Therapies, Inc.'s capex?
- Taysha Gene Therapies, Inc. (TSHA) reported capex of $24K in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s capex changed year-over-year?
- Taysha Gene Therapies, Inc.'s capex decreased by 93.7% year-over-year, from $378K to $24K.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s capex?
- Over 3 years (2021 to 2025), Taysha Gene Therapies, Inc.'s capex has grown at a -63.6% compound annual growth rate (CAGR), from $15.3M to $738K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Taysha Gene Therapies, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude